Private company

Rubius Therapeutics (United States)

Logo: rubiustx.com³

American biological products company based in Cambridge, founded in 2013.¹

Last updated Oct 18, 2026.

Overview

2013Founded¹

IndustryBiological Products, (No Diagnostic Substances)¹
HeadquartersCambridge, United States¹
Websitewww.rubiustx.com
Legal formDelaware corporation¹
Incorporated inDE⁴
Business addressC/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101, Foxboro, Ma 02035⁴
Filer categoryNon-accelerated filer, Smaller reporting company⁴

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1187.4%Return on equity⁵

0.00×Debt to equity⁵

-$155.4MFree cash flow⁵

Financial statements

Revenue⁵$0 in 2022

Operating income⁶⁷⁸⁹⁵-$178.4M in 2022+1544% since 2016

Net income⁶⁷⁸⁹⁵-$179.7M in 2022+1531% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue					$0⁵	$0⁵	$0⁵
Research and development	$8.4M⁶	$21.2M⁷	$51.8M⁸	$112.4M⁹	$116.1M⁵	$141.6M⁵	$96.4M⁵
Operating income	-$10.9M⁶	-$43.3M⁷	-$91.7M⁸	-$169.6M⁹	-$166.4M⁵	-$194.6M⁵	-$178.4M⁵
Interest	$149.0K⁶	$309.0K⁷	$464.0K⁸	$2.6M⁹	$4.2M⁵	$6.4M⁵	$3.9M⁵
Net income	-$11.0M⁶	-$43.8M⁷	-$89.2M⁸	-$163.5M⁹	-$167.7M⁵	-$196.5M⁵	-$179.7M⁵
Earnings per share					-$2.08⁵	-$2.23⁵	-$1.99⁵
Earnings per share (diluted)					-$2.08⁵	-$2.23⁵	-$1.99⁵

Total assets⁶⁷⁸⁹⁵$23.1M in 2022−79% since 2017

Total liabilities⁶⁷⁸⁹⁵$7.9M in 2022−31% since 2017

Shareholders’ equity⁷⁸⁹⁵$15.1M in 2022

Cash⁷⁶⁸⁹⁵$14.9M in 2022+110% since 2016

Long-term debt⁶⁷⁸⁹⁵$0 in 2022

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$7.1M⁷	$104.3M⁶	$307.1M⁷	$91.9M⁸	$91.2M⁹	$225.8M⁵	$14.9M⁵
Current assets		$105.0M⁶	$414.4M⁷	$289.3M⁸	$181.5M⁹	$229.8M⁵	$20.2M⁵
Total assets		$107.7M⁶	$479.1M⁷	$394.8M⁸	$277.8M⁹	$318.0M⁵	$23.1M⁵
Current liabilities		$7.2M⁶	$20.0M⁷	$33.8M⁸	$27.8M⁹	$34.7M⁵	$7.9M⁵
Long-term debt		$3.3M⁶	$24.3M⁷	$49.6M⁸	$74.9M⁹	$76.2M⁵	$0⁵
Total liabilities		$11.6M⁶	$86.1M⁷	$120.6M⁸	$136.2M⁹	$139.2M⁵	$7.9M⁵
Shareholders’ equity	-$17.1M⁷	-$43.7M⁸	$393.0M⁹	$274.2M⁵	$141.6M⁵	$178.8M⁵	$15.1M⁵
Shares outstanding		15.0M shares⁶	79.2M shares⁷	80.0M shares⁸	81.1M shares⁹	90.1M shares⁵	90.4M shares⁵

Cash from operations⁶⁷⁸⁹⁵-$150.1M in 2022+1480% since 2016

Capital spending⁶⁷⁸⁹⁵$5.3M in 2022+1097% since 2016

Free cash flow⁶⁷⁸⁹⁵-$155.4M in 2022+1463% since 2016

Share buybacks⁹⁵$75.7M in 2022+61951% since 2019

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations	-$9.5M⁶	-$21.9M⁷	-$58.3M⁸	-$110.4M⁹	-$127.6M⁵	-$145.1M⁵	-$150.1M⁵
Capital spending	$443.0K⁶	$2.3M⁷	$15.0M⁸	$40.7M⁹	$5.5M⁵	$3.6M⁵	$5.3M⁵
Free cash flow	-$9.9M	-$24.2M	-$73.3M	-$151.1M	-$133.1M	-$148.8M	-$155.4M
Share buybacks				$122.0K⁹	$0⁵	$0⁵	$75.7M⁵

Compare Rubius Therapeutics (United States) with another company

Leadership

Who has led Rubius Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Dannielle Appelhans2021–2022

201520202025

Chief executive officerDannielle Appelhans Feb 1, 2023 to Feb 27, 2023¹²
Chief executive officerPablo J. Cagnoni Jul 17, 2018 to Feb 14, 2022¹³
PresidentDannielle Appelhans Feb 1, 2023 to Feb 27, 2023¹²
PresidentPablo J. Cagnoni Apr 15, 2020 to Feb 14, 2022¹⁴
PresidentTorben Straight Nissen Jul 17, 2018 to Jul 26, 2019¹⁵
Chief financial officerJose Carmona Oct 8, 2020 to Feb 1, 2022¹⁶
Chief financial officerAndrew M. Oh Jul 17, 2018 to May 19, 2020¹⁷
Chief operating officerDannielle Appelhans Aug 16, 2021 to Aug 12, 2022¹⁸

Board members and other officers (14)

Chief Scientific OfficerLaurence A. Turka Jan 28, 2020 to Jan 31, 2023¹⁹
Chief Medical OfficerChristopher L. Carpenter Jul 17, 2018 to Dec 18, 2019²⁰
Board memberSusanne Schaffert Jul 19, 2022 to Aug 1, 2022²¹
Board memberNatalie C. Holles Mar 27, 2019 to May 13, 2022²²
Board memberAnne Prener Dec 26, 2019 to May 13, 2022²³
Board memberCatherine A. Sohn Jul 17, 2018 to May 13, 2022²⁴
Board memberDavid R. Epstein Jul 17, 2018 to May 13, 2022²⁵
Board memberFrancis M. Cuss Jul 17, 2018 to May 13, 2022²⁶
Board memberMichael Rosenblatt Jul 17, 2018 to May 13, 2022²⁷
Board memberNoubar Afeyan Jul 17, 2018 to May 13, 2022²⁸
Board memberPablo J. Cagnoni Jul 17, 2018 to Feb 1, 2023¹³
Board memberRobert S. Langer, Jr. Jul 17, 2018 to Oct 17, 2019²⁹
Board memberRoger Pomerantz Jul 17, 2018 to Jul 23, 2018³⁰
General counselMaiken Keson-Brookes Nov 20, 2019 to Feb 1, 2022³¹

Timeline

Feb 1, 2023New chief executive Dannielle Appelhans becomes CEO¹²
Jul 17, 2018New chief executive Pablo J. Cagnoni becomes CEO¹³
2013Founded Founded¹

Filings

80 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 22 major events, 23 insider forms, 9 large holders, 20 other. The latest 20:

Apr 10, 202315-12G EDGAR
Apr 10, 2023SC 13G/A EDGAR
Apr 6, 20238-K EDGAR
Mar 28, 202325 EDGAR
Mar 9, 2023DEF 14A EDGAR
Mar 3, 20238-K EDGAR
Mar 3, 2023SC 13G/A EDGAR
Mar 2, 2023PRER14A EDGAR
Feb 27, 202310-K EDGAR
Feb 27, 20234 OWNERSHIP DOCUMENT EDGAR
Feb 27, 2023PRE 14A EDGAR
Feb 27, 2023S-8 POS EDGAR
Feb 27, 2023S-8 POS EDGAR
Feb 27, 2023S-8 POS EDGAR
Feb 27, 2023S-8 POS EDGAR
Feb 27, 2023S-8 POS EDGAR
Feb 22, 2023RW EDGAR
Feb 22, 20238-K EDGAR
Feb 14, 2023SC 13G/A EDGAR
Feb 9, 2023SC 13G/A EDGAR

The 80 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 9 such filings since October 2021:

Apr 10, 2023SC 13G/A
Mar 3, 2023SC 13G/A
Feb 14, 2023SC 13G/A
Feb 9, 2023SC 13G/A
Jan 20, 2023SC 13G/A
Feb 14, 2022SC 13G/A
Feb 11, 2022SC 13G/A
Feb 9, 2022SC 13G/A
Jan 26, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataRubius Therapeutics (United States) on Wikidata
2
SEC EDGARRubius Therapeutics (United States) filings on SEC EDGAR
3
Company websiteRubius Therapeutics (United States) logo
4
SEC EDGARRubius Therapeutics (United States) filings on SEC EDGAR
5
SEC EDGARRubius Therapeutics (United States) 10-K for fiscal 2022
6
SEC EDGARRubius Therapeutics (United States) 10-K for fiscal 2016
7
SEC EDGARRubius Therapeutics (United States) 10-K for fiscal 2017
8
SEC EDGARRubius Therapeutics (United States) 10-K for fiscal 2018
9
SEC EDGARRubius Therapeutics (United States) 10-K for fiscal 2019
10
SEC EDGARRubius Therapeutics (United States) 10-Q for fiscal 2022
11
SEC EDGARRubius Therapeutics (United States) 10-Q for fiscal 2022
12
SEC EDGARDannielle Appelhans, Chief executive officer
13
SEC EDGARPablo J. Cagnoni, Chief executive officer
14
SEC EDGARPablo J. Cagnoni, President
15
SEC EDGARTorben Straight Nissen, President
16
SEC EDGARJose Carmona, Chief financial officer
17
SEC EDGARAndrew M. Oh, Chief financial officer
18
SEC EDGARDannielle Appelhans, Chief operating officer
19
SEC EDGARLaurence A. Turka, Chief Scientific Officer
20
SEC EDGARChristopher L. Carpenter, Chief Medical Officer
21
SEC EDGARSusanne Schaffert, Board member
22
SEC EDGARNatalie C. Holles, Board member
23
SEC EDGARAnne Prener, Board member
24
SEC EDGARCatherine A. Sohn, Board member
25
SEC EDGARDavid R. Epstein, Board member
26
SEC EDGARFrancis M. Cuss, Board member
27
SEC EDGARMichael Rosenblatt, Board member
28
SEC EDGARNoubar Afeyan, Board member
29
SEC EDGARRobert S. Langer, Jr., Board member
30
SEC EDGARRoger Pomerantz, Board member
31
SEC EDGARMaiken Keson-Brookes, General counsel